Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

• Benoît Baras,

  Affiliation Preclinical Virology, GlaxoSmithKline Biologicals, Rixensart, Belgium

  ⨯
• Koert J. Stittelaar,

  Affiliation ViroClinics BV, Rotterdam, The Netherlands

  ⨯
• James H. Simon,

  Affiliation ViroClinics BV, Rotterdam, The Netherlands

  ⨯
• Robert J. M. M. Thoolen,

  Affiliation Global Pathology Support, Toxicologic Pathology, The Hague, The Netherlands

  ⨯
• Sally P. Mossman,

  Affiliation Preclinical Virology, GlaxoSmithKline Biologicals, Rixensart, Belgium

  ⨯
• Frank H. M. Pistoor,

  Affiliation ViroClinics BV, Rotterdam, The Netherlands

  ⨯
• Geert van Amerongen,

  Affiliation ViroClinics BV, Rotterdam, The Netherlands

  ⨯
• Martine A. Wettendorff,

  Affiliation Preclinical Virology, GlaxoSmithKline Biologicals, Rixensart, Belgium

  ⨯
• Emmanuel Hanon,

  Affiliation Preclinical Virology, GlaxoSmithKline Biologicals, Rixensart, Belgium

  ⨯
• Albert D. M. E. Osterhaus

  *To whom correspondence should be addressed. E-mail: a.osterhaus@erasmusmc.nl

  Affiliations ViroClinics BV, Rotterdam, The Netherlands, Department of Virology, Erasmus Medical Center (MC), Rotterdam, The Netherlands

  ⨯